cropped color_logo_with_background.png

Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma

Study Purpose

This study seeks to evaluate the tolerability, pharmacokinetics (PK), efficacy, and safety of ABT-414 in Japanese participants with newly diagnosed and recurrent, World Health Organization (WHO) grade III or IV malignant glioma.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 20 Years - 99 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Japanese participants with WHO grade III or IV malignant glioma.
  • - 70 or above on Karnofsky Performance Status in Arm A of Phase 1 portion and Phase 2 portion.
  • - 80 or above on Karnofsky Performance Status in Arm B and Arm C of Phase 1 portion.
  • - Adequate bone marrow function.
  • - Recurrent malignant glioma per RANO criteria in Arm A of Phase 1 portion and Phase 2 portion.
  • - Histologically proven newly diagnosed malignant glioma in Arm B and Arm C of Phase 1 portion.
  • - Participants must have confirmed EGFR amplification by central lab in Phase 2 portion.

Exclusion Criteria:

  • - Anti-cancer treatment 28 days prior to study Day 1 for Arm A of Phase 1 portion and Phase 2 portion (except temozolomide therapy for newly diagnosed treatment for Phase 2 portion) - Anti-cancer treatment prior to study Day 1 for Arm B and Arm C of Phase 1 portion.
  • - Participant has received prior treatment with bevacizumabor, EGFR therapy in Arm A of Phase 1 portion and Phase 2 portion, or for recurrent glioblastoma in Phase 2 portion.
  • - Participant has a history of major immunologic reaction to any Immunoglobulin G containing agents or component of ABT-414.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT02590263
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 1/Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

AbbVie
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

AbbVie Inc.
Principal Investigator Affiliation AbbVie
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Completed
Countries Japan
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Malignant Glioma, Glioblastoma Multiforme
Arms & Interventions

Arms

Experimental: Arm A of Phase 1 portion

ABT-414 administered every other weeks monotherapy

Experimental: Phase 2 portion

ABT-414 administered every other weeks in combination with temozolomide

Experimental: Arm C of Phase 1 portion

ABT-414 administered every other weeks in combination with radiation and temozolomide

Experimental: Arm B of Phase 1 portion

ABT-414 administered every other weeks in combination with radiation and temozolomide

Interventions

Radiation: - Whole Brain Radiation

Whole Brain Radiation will be administered in over 30 fractions as per the procedure in each study site.

Drug: - Temozolomide

Temozolomide will be administered per label.

Drug: - ABT-414

ABT-414 will be administered by intravenous infusion

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Nagoya University Hospital /ID# 138559, Nagoya-shi, Aichi, Japan

Status

Address

Nagoya University Hospital /ID# 138559

Nagoya-shi, Aichi, 466-8560

Hiroshima-shi, Hiroshima, Japan

Status

Address

Hiroshima University Hospital /ID# 139399

Hiroshima-shi, Hiroshima, 734-8551

Hokkaido University Hospital /ID# 150589, Sapporo-shi, Hokkaido, Japan

Status

Address

Hokkaido University Hospital /ID# 150589

Sapporo-shi, Hokkaido, 060-8648

Tsukuba-shi, Ibaraki, Japan

Status

Address

University of Tsukuba Hospital /ID# 140433

Tsukuba-shi, Ibaraki, 305-8576

Shiwa-gun, Iwate, Japan

Status

Address

Iwate Medical University Hospital /ID# 149145

Shiwa-gun, Iwate, 028-3695

Kitasato University Hospital /ID# 148493, Sagamihara-shi, Kanagawa, Japan

Status

Address

Kitasato University Hospital /ID# 148493

Sagamihara-shi, Kanagawa, 252-0375

Kumamoto University Hospital /ID# 138558, Kumamoto-shi, Kumamoto, Japan

Status

Address

Kumamoto University Hospital /ID# 138558

Kumamoto-shi, Kumamoto, 860-8556

Kyoto Prefect Univ Med /ID# 149093, Kyoto-shi, Kyoto, Japan

Status

Address

Kyoto Prefect Univ Med /ID# 149093

Kyoto-shi, Kyoto, 602-8566

Kyoto University Hospital /ID# 163206, Kyoto-shi, Kyoto, Japan

Status

Address

Kyoto University Hospital /ID# 163206

Kyoto-shi, Kyoto, 606-8507

Tohoku University Hospital /ID# 138464, Sendai-shi, Miyagi, Japan

Status

Address

Tohoku University Hospital /ID# 138464

Sendai-shi, Miyagi, 980-8574

Okayama University Hospital /ID# 148674, Okayama-shi, Okayama, Japan

Status

Address

Okayama University Hospital /ID# 148674

Okayama-shi, Okayama, 700-8558

Osaka University Hospital /ID# 140438, Suita-shi, Osaka, Japan

Status

Address

Osaka University Hospital /ID# 140438

Suita-shi, Osaka, 565-0871

Hidaka-shi, Saitama, Japan

Status

Address

Saitama Medical University International Medical Center /ID# 140361

Hidaka-shi, Saitama, 350-1298

Shizuoka Cancer Center /ID# 148673, Sunto-gun, Shizuoka, Japan

Status

Address

Shizuoka Cancer Center /ID# 148673

Sunto-gun, Shizuoka, 411-8777

Shimotsuga-gun, Tochigi, Japan

Status

Address

Dokkyo Medical University Hospital /ID# 150990

Shimotsuga-gun, Tochigi, 321-0293

Chuo-ku, Tokyo, Japan

Status

Address

National Cancer Center Hospital /ID# 140435

Chuo-ku, Tokyo, 104-0045

Itabashi-ku, Tokyo, Japan

Status

Address

Nihon University Itabashi Hospital /ID# 149385

Itabashi-ku, Tokyo, 173-0032

Kyorin University Hospital /ID# 140360, Mitaka-shi, Tokyo, Japan

Status

Address

Kyorin University Hospital /ID# 140360

Mitaka-shi, Tokyo, 181-8611

Shinjuku-ku, Tokyo, Japan

Status

Address

Tokyo Women's Medical University Hospital /ID# 140436

Shinjuku-ku, Tokyo, 162-8666

Chiba Cancer Center /ID# 164375, Chiba, Japan

Status

Address

Chiba Cancer Center /ID# 164375

Chiba, , 260-0801

NHO Kyoto Medical Center /ID# 140437, Kyoto, Japan

Status

Address

NHO Kyoto Medical Center /ID# 140437

Kyoto, , 612-0861

Osaka, Japan

Status

Address

Osaka International Cancer Institute /ID# 148494

Osaka, , 541-8567